105 related articles for article (PubMed ID: 2275874)
1. Immunocytochemical evaluation of proliferative activity in human brain tumours.
Girino M; Riccardi A; Danova M; Gaetani P; Butti G; Giordano M; Cuomo A
Anal Cell Pathol; 1990 Sep; 2(5):269-75. PubMed ID: 2275874
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical detection of proliferative cells.
Mokrý J; Nĕmecek S
Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove; 1995; 38(3):107-13. PubMed ID: 8685626
[TBL] [Abstract][Full Text] [Related]
3. Relationship between Ki-67 positive cells, growth rate and histological type of human intracranial tumors.
Patsouris E; Stocker U; Kallmeyer V; Keiditsch E; Mehraein P; Stavrou D
Anticancer Res; 1988; 8(4):537-44. PubMed ID: 3052245
[TBL] [Abstract][Full Text] [Related]
4. In vivo bromodeoxyuridine labelling index, AgNOR protein expression and DNA content in human tumours.
Trerè D; Ceccarelli C; Danova M; Derenzini M
Eur J Histochem; 1996; 40(1):17-26. PubMed ID: 8741096
[TBL] [Abstract][Full Text] [Related]
5. Direct comparison of bromodeoxyuridine and Ki-67 labelling indices in human tumours.
Wilson GD; Saunders MI; Dische S; Daley FM; Robinson BM; Martindale CA; Joiner B; Richman PI
Cell Prolif; 1996 Mar; 29(3):141-52. PubMed ID: 8652743
[TBL] [Abstract][Full Text] [Related]
6. Immunocytochemical detection of cell proliferation-related antigens in cytologic smears of human malignant neoplasms using PC10, reactive with proliferating cell nuclear antigen, and Ki-67. A comparative study.
Pelosi G; Bresaola E; Manfrin E; Rodella S; Schiavon I; Iannucci A
Arch Pathol Lab Med; 1994 May; 118(5):510-6. PubMed ID: 7910728
[TBL] [Abstract][Full Text] [Related]
7. Determination of proliferative activities in human brain tumor specimens: a comparison of three methods.
Morimura T; Kitz K; Stein H; Budka H
J Neurooncol; 1991 Feb; 10(1):1-11. PubMed ID: 2022970
[TBL] [Abstract][Full Text] [Related]
8. Measurement of labeling index of DNA polymerase alpha in human brain tumors. Comparative study with labeling indices of BUdR in vitro and Ki-67.
Nishizaki T; Orita T; Kamiryo T; Akimura T; Kajiwara K; Ikeda N; Ohshita N; Ito H; Sasaki K
Clin Neuropathol; 1993; 12(3):160-3. PubMed ID: 8324965
[TBL] [Abstract][Full Text] [Related]
9. Proliferating cell nuclear antigen (PCNA) immunostaining as an alternative to bromodeoxyuridine (BrdU) immunostaining for brain tumours in paraffin embedded sections.
Sasaki A; Naganuma H; Kimura R; Isoe S; Nakano S; Nukui H; Suzuki K; Kawaoi A
Acta Neurochir (Wien); 1992; 117(3-4):178-81. PubMed ID: 1357920
[TBL] [Abstract][Full Text] [Related]
10. Correlation between the bromodeoxyuridine labeling index and the MIB-1 and Ki-67 proliferating cell indices in cerebral gliomas.
Onda K; Davis RL; Shibuya M; Wilson CB; Hoshino T
Cancer; 1994 Oct; 74(7):1921-6. PubMed ID: 7521787
[TBL] [Abstract][Full Text] [Related]
11. AgNOR area in interphase nuclei of human tumours correlates with the proliferative activity evaluated by bromodeoxyuridine labelling and Ki-67 immunostaining.
Trerè D; Farabegoli F; Cancellieri A; Ceccarelli C; Eusebi V; Derenzini M
J Pathol; 1991 Sep; 165(1):53-9. PubMed ID: 1955936
[TBL] [Abstract][Full Text] [Related]
12. [A cell kinetic study of human central nervous system tumors with 5-bromodeoxyuridine (BrdU)].
Nagashima T; Hoshino T
No To Shinkei; 1985 Dec; 37(12):1195-201. PubMed ID: 3912000
[TBL] [Abstract][Full Text] [Related]
13. Monoclonal antibody to stage-specific fetal brain 68-kDa glycoprotein (FGP68) revealed increased FGP68 expression in human primary brain tumors.
Kato S; Shinozawa T; Nagashige H; Nakamura M; Asano Y; Takikawa M; Kato M; Awaya A; Hirano A; Ohama E
Acta Neuropathol; 2002 Jul; 104(1):57-66. PubMed ID: 12070665
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical analysis of metallothionein in astrocytic tumors in relation to tumor grade, proliferative potential, and survival.
Hiura T; Khalid H; Yamashita H; Tokunaga Y; Yasunaga A; Shibata S
Cancer; 1998 Dec; 83(11):2361-9. PubMed ID: 9840536
[TBL] [Abstract][Full Text] [Related]
15. [Cellular kinetics of cerebral glioma: study of the proliferative activity using monoclonal antibody Ki 67. Apropos of 60 cases].
Parent M; Blond S; Gosset P; Lejeune JP; Lesoin F; Dhellemmes P; Jomin M; Christiaens JL; Dupont A
Arch Anat Cytol Pathol; 1990; 38(3):81-5. PubMed ID: 2363592
[TBL] [Abstract][Full Text] [Related]
16. Proliferation, bcl-2 expression and angiogenesis in pituitary adenomas: relationship to tumour behaviour.
Turner HE; Nagy Z; Gatter KC; Esiri MM; Wass JA; Harris AL
Br J Cancer; 2000 Apr; 82(8):1441-5. PubMed ID: 10780524
[TBL] [Abstract][Full Text] [Related]
17. Nucleolar organizer region score and Ki-67 labelling index in high-grade gliomas and metastatic brain tumours.
Hara A; Hirayama H; Sakai N; Yamada H; Tanaka T; Mori H
Acta Neurochir (Wien); 1991; 109(1-2):37-41. PubMed ID: 1648862
[TBL] [Abstract][Full Text] [Related]
18. In situ analysis of cell kinetics in human brain tumors. A comparative immunocytochemical study of S phase cells by a new in vitro bromodeoxyuridine-labeling technique, and of proliferating pool cells by monoclonal antibody Ki-67.
Morimura T; Kitz K; Budka H
Acta Neuropathol; 1989; 77(3):276-82. PubMed ID: 2922990
[TBL] [Abstract][Full Text] [Related]
19. PCNA, Ki-67 and hTERT in residual benign meningiomas.
Maes L; Kalala JP; Cornelissen M; De Ridder L
In Vivo; 2006; 20(2):271-5. PubMed ID: 16634530
[TBL] [Abstract][Full Text] [Related]
20. Proliferative activity of chosen central nervous system (CNS) neoplasms.
Lebelt A; Szkudlarek M; Guzińska-Ustymowicz K; Lemancewicz D; Zimnoch L; Dziecioł J
Rocz Akad Med Bialymst; 2004; 49 Suppl 1():242-3. PubMed ID: 15638437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
